Fondaparinux vs heparin
Recurrent VTE · patients with cancer with venous thromboembolism
Fondaparinux showed no clear difference in recurrent VTE compared with heparin (low certainty).
1 finding from 1 review
- Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes onlyRR 0.93 [0.56, 1.54]1 study · 477 participantsLow